Related references
Note: Only part of the references are listed.EGFR endocytosis is a novel therapeutic target in lung cancer with wild-type EGFR
Ukhyun Jo et al.
ONCOTARGET (2014)
USP8 Is a Novel Target for Overcoming Gefitinib Resistance in Lung Cancer
Sanguine Byun et al.
CLINICAL CANCER RESEARCH (2013)
Galectin-3 expression in prostate cancer and benign prostate tissues: correlation with biochemical recurrence
Judith S. Knapp et al.
WORLD JOURNAL OF UROLOGY (2013)
Galectin-3 Regulates Intracellular Trafficking of EGFR through Alix and Promotes Keratinocyte Migration
Wei Liu et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2012)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
KRAS Mutation in Colon Cancer: A Marker of Resistance to EGFR-I Therapy
Ahmad D. Siddiqui et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
Galectin-3 expression is associated with bladder cancer progression and clinical outcome
Giacomo Canesin et al.
TUMOR BIOLOGY (2010)
Identification of Biomarkers in Human Head and Neck Tumor Cell Lines That Predict For In Vitro Sensitivity to Gefitinib
D. Mark Hickinson et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2009)
Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma - Tissue effect predicts clinical response
Milind Javle et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2008)
Gefitinib-sensitizing mutation in esophageal carcinoma cell line Kyse450
MZ Guo et al.
CANCER BIOLOGY & THERAPY (2006)
Antitumor effect of gefitinib ('Iressa') on esophageal squamous cell carcinoma cell lines in vitro and in vivo
F Hara et al.
CANCER LETTERS (2005)
ZD1839 (Gefitinib, 'Iressa'), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma
F Teralshi et al.
FEBS LETTERS (2005)
On the role of galectin-3 in cancer apoptosis
S Nakahara et al.
APOPTOSIS (2005)
Common and distinct elements in cellular signaling via EGF and FGF receptors
J Schlessinger
SCIENCE (2004)
Epidermal growth factor receptor regulates aberrant expression of insulin-like growth factor-binding protein 3
M Takaoka et al.
CANCER RESEARCH (2004)
Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis
EA Partridge et al.
SCIENCE (2004)
Medical progress - Esophageal cancer
PC Enzinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Galectin-3 and metastasis
Y Takenaka et al.
GLYCOCONJUGATE JOURNAL (2002)
The EGF receptor family as targets for cancer therapy
J Mendelsohn et al.
ONCOGENE (2000)
Share Paper
